Filing search / Adaptimmune Therapeutics plc / "Access"

8-K

EX-99.1

ADAP Adaptimmune Therapeutics plc

2 Aug 24

Approved for advanced MAGE-A4+synovial sarcoma in adults with certain HLA types who have received prior chemotherapy

7:00am

access to medications and resuscitative equipment to manage CRS. CRS occurred in 75% of patients (2% Grade ≥3) with a median onset of 2 days (range … . Monitoring for CRS and ICANS During and Following TECELRA Infusion Ensure that healthcare providers administering TECELRA have immediate access

8-K

EX-10.1

ADAP Adaptimmune Therapeutics plc

16 Jul 24

Departure of Directors or Certain Officers

4:30pm

of charge, reasonable access to and copies of all pertinent documents, records and other information that is relevant to his or her claim for benefits … the denial of Executive’s claim is based; (iii)a statement that Executive is entitled to receive, upon request and free of charge, reasonable access

8-K

EX-10.1

ADAP Adaptimmune Therapeutics plc

11 Jun 24

Departure of Directors or Certain Officers

4:15pm

has the right to be provided with, upon request and free of charge, reasonable access to and copies of all pertinent documents, records and other … to receive, upon request and free of charge, reasonable access to, and copies of, the Policy and all documents, records, and other information relevant

8-K

EX-99.1

zm337s71xxixxbx

30 May 24

Entry into a Material Definitive Agreement

4:09pm

8-K

EX-99.1

hos21wridzilaabu5uo

27 Feb 24

Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company’s Sarcoma Franchise

8:13am

8-K

EX-99.1

ashvi 91t1iw

8 Nov 23

Adaptimmune Reports Third Quarter Financial Results and Business Update

7:37am

8-K

EX-10.3

nticoz3wx22 oxdi

1 Jun 23

Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company

4:09pm

8-K

EX-10.4

x0qvi qdly4roo6

1 Jun 23

Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company

4:09pm

8-K

EX-10.1

mim72 pg0

1 Jun 23

Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company

4:09pm

8-K

EX-10.2

xh6agj2l66sb

1 Jun 23

Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company

4:09pm

8-K

EX-99.1

bdvse5jds i6y4yal7

1 Jun 23

Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company

4:09pm

424B3

3mmnw4165i8qn1

20 Apr 23

Prospectus supplement

4:32pm

S-4/A

1e9mli 2dn6d9

18 Apr 23

Registration of securities issued in business combination transactions (amended)

4:01pm